Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of HRS-2189 Combined HRS-5041 in Metastatic Prostate Cancer

NCT06738745 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06738745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06738745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of HRS-2189 Combined HRS-5041 in Metastatic Prostate Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2024
Completion date
August 31, 2027
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic disease